THOUSAND OAKS, Calif.,
March 23, 2015 /PRNewswire/
-- Amgen (NASDAQ:AMGN) will host a webcast call for the
investment community at the 73rd Annual Meeting of the
American Academy of Dermatology (AAD) on Monday, March 23, 2015, at 1 p.m. PT. The webcast will begin one hour
later than previously announced on March 17,
2015, to accommodate scheduling changes. Elliott M. Levy, M.D., executive vice president
of Research and Development at Amgen, along with members of Amgen's
clinical development team and clinical investigators, will
participate in this call to discuss Amgen's clinical data presented
at AAD, including the brodalumab Phase 3 results.
Live audio of the investor call will be simultaneously broadcast
over the Internet and will be available to members of the news
media, investors and the general public.
The webcast, as with other selected presentations regarding
developments in Amgen's business given by management at certain
investor and medical conferences, can be found on Amgen's website,
www.amgen.com, under Investors. Information regarding presentation
times, webcast availability and webcast links are noted on Amgen's
Investor Relations Events Calendar. The webcast will be archived
and available for replay for at least 90 days after the
event.
About Amgen
Amgen is committed to unlocking the
potential of biology for patients suffering from serious illnesses
by discovering, developing, manufacturing and delivering innovative
human therapeutics. This approach begins by using tools like
advanced human genetics to unravel the complexities of disease and
understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages
its biologics manufacturing expertise to strive for solutions that
improve health outcomes and dramatically improve people's lives. A
biotechnology pioneer since 1980, Amgen has grown to be one of the
world's leading independent biotechnology companies, has reached
millions of patients around the world and is developing a pipeline
of medicines with breakaway potential.
For more information, visit www.amgen.com and follow us on
www.twitter.com/amgen.
CONTACT: Amgen, Thousand
Oaks
Kristen Davis, 805-447-3008
(media)
Cuyler Mayer, 805-447-6332
(media)
Arvind Sood, 805-447-1060
(investors)
Logo - http://photos.prnewswire.com/prnh/20081015/AMGENLOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/amgen-to-webcast-investor-call-at-the-73rd-annual-meeting-of-the-american-academy-of-dermatology-300054148.html
SOURCE Amgen